News

BioAtla's Upcoming Presentation on Mecbotamab Vedotin in Sarcoma

BioAtla's Upcoming Presentation on Mecbotamab Vedotin in Sarcoma

BioAtla's Key Clinical Presentation at SITC 2025

BioAtla, Inc. (NASDAQ: BCAB), an innovative biotechnology company, is preparing to present its latest findings on mecbotamab vedotin (BA3011), an AXL-targeting antibody-drug conjugate (ADC), at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. This event will occur from November 5 to 9, 2025.

Mecbotamab Vedotin in Focus

The clinical data that will be presented highlights significant outcomes for patients suffering from treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. The presentation, titled "Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC," aims to shed light on the potential of BA3011 as a transformative therapy.

Expert Insights from Dr. Mihaela Druta

Dr. Mihaela Druta from Moffitt Cancer Center will lead the presentation on November 7, 2025. This pivotal discussion will take place as part of a poster session at the conference, offering valuable insights into the efficacy and safety profile of the investigational drug.

Accessing Presentation Materials

Following the presentation, interested parties can access comprehensive materials regarding the findings on BioAtla's official website in the 'Publication' section. This resource will become available at the end of the presentation, providing deeper insights into the research.

Understanding BioAtla, Inc.

BioAtla is dedicated to developing novel therapeutics using its proprietary Conditionally Active Biologic (CAB) platform, which is designed to create antibodies with enhanced targeting and efficiency. With operations in both the U.S. and China, BioAtla is committed to advancing care in oncology through innovative treatment options. The company holds a robust patent portfolio that encompasses over 780 active patent matters, positioning itself as a leader in the biotechnology industry.

Future of Cancer Therapies

As BioAtla continues to push boundaries, their advancements in therapy development aim at making significant strides in treating various types of solid tumors, including sarcomas. The upcoming presentation at SITC 2025 is a testament to their commitment to innovation in cancer treatment.

Key Contacts at BioAtla

For further inquiries, Richard Waldron, Chief Financial Officer at BioAtla, can be contacted at 858.356.8945 or via email at rwaldron@bioatla.com. For external communications, Joyce Allaire with LifeSci Advisors is available for questions at jallaire@lifesciadvisors.com.

Frequently Asked Questions

What is mecbotamab vedotin?

Mecbotamab vedotin (BA3011) is an investigational antibody-drug conjugate developed by BioAtla targeting AXL to treat solid tumors.

When will the presentation of clinical data occur?

The presentation will take place on November 7, 2025, at the SITC Annual Meeting.

Who is delivering the presentation?

The presentation will be delivered by Dr. Mihaela Druta from Moffitt Cancer Center.

How can I access the presentation materials?

Presentation materials will be available in the 'Publication' section of BioAtla's website after the presentation concludes.

What is the significance of this research?

This research highlights essential advancements in the treatment of sarcomas, demonstrating the potential impact of mecbotamab vedotin on patient outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 50

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading

Top 5 Most Recently Viewed Articles

Darja Bolshakova Takes the Helm as CFO at Arco Vara Group

Updated Category News Views 239

Darja Bolshakova Appointed as New CFO of Arco Vara The Management Board of Arco Vara AS is excited to announce the appointment of Darja Bolshakova as the Chief Financial Officer. This strategic move is aimed at enhancing the leadership team as the company continues to grow and navigate through evolving market conditions. Years of Expertise in Finance Darja Bolshakova...

Continue Reading
TruGolf Partners with Golf Everywhere for Innovative Facility

Updated Category News Views 175

TruGolf Selected as Exclusive Supplier for Golf Everywhere TruGolf Holdings, Inc. (NASDAQ: TRUG) is thrilled to announce its role as the exclusive golf simulator supplier for the upcoming Golf Everywhere facility, which is set to break ground later this year. This facility, measuring approximately six acres, will become the largest indoor golf venue in the United States,...

Continue Reading
Navigator Unveils Innovative Platform for Local Government Funding

Updated Category News Views 248

Navigator Launches to Revolutionize Local Government Funding Navigator is on a mission to connect communities across the nation with billions of dollars in funding opportunities. By introducing two groundbreaking solutions—Funding Navigator and Pipeline Navigator—this innovative platform helps organizations of all sizes simplify their grant applications and break...

Continue Reading
CData Unveils Integration Accelerator to Streamline Data Workflows

Updated Category News Views 253

CData Unveils Innovative Integration Accelerator for Databricks Purpose-built solution reduces data pipeline complexity and accelerates integration across hybrid and multi-cloud Databricks environments. CData, a prominent player in the data connectivity and integration landscape, has announced an exciting advancement with the launch of its Integration Accelerator designed...

Continue Reading
Goldman Sachs Boosts Weyerhaeuser’s Potential with Buy Rating

Updated Category News Views 75

Goldman Sachs Affirms Weyerhaeuser's Growth Potential Goldman Sachs has recently confirmed its optimistic view of Weyerhaeuser (NYSE: WY) by maintaining a Buy rating and setting a price target of $38.00. This announcement follows insightful discussions with the company's leadership, including Chief Financial Officer Davie Wold and Vice President of Investor Relations Andy...

Continue Reading